MX2023010317A - Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. - Google Patents
Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.Info
- Publication number
- MX2023010317A MX2023010317A MX2023010317A MX2023010317A MX2023010317A MX 2023010317 A MX2023010317 A MX 2023010317A MX 2023010317 A MX2023010317 A MX 2023010317A MX 2023010317 A MX2023010317 A MX 2023010317A MX 2023010317 A MX2023010317 A MX 2023010317A
- Authority
- MX
- Mexico
- Prior art keywords
- indole derivatives
- treatment
- agents useful
- disorders related
- disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 208000035475 disorder Diseases 0.000 title abstract 3
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 title 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical class C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente solicitud se refiere a derivados de 3-amino-indol de la Fórmula general (I-A), a procesos para su preparación, a composiciones que los comprenden y a su uso en la activación de receptores de serotonina en una célula, así como al tratamiento de enfermedades, trastornos o condiciones por activación de receptores de serotonina en una célula. Las enfermedades, trastornos o afecciones incluyen, por ejemplo, psicosis, enfermedades mentales y trastornos del SNC. (ver formula) Fórmula (I-A).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155634P | 2021-03-02 | 2021-03-02 | |
| PCT/CA2022/050295 WO2022183287A1 (en) | 2021-03-02 | 2022-03-02 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010317A true MX2023010317A (es) | 2023-11-09 |
Family
ID=83153685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010316A MX2023010316A (es) | 2021-03-02 | 2022-03-02 | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
| MX2023010317A MX2023010317A (es) | 2021-03-02 | 2022-03-02 | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010316A MX2023010316A (es) | 2021-03-02 | 2022-03-02 | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240166599A1 (es) |
| EP (2) | EP4301747A1 (es) |
| JP (2) | JP2024508922A (es) |
| KR (2) | KR20230154220A (es) |
| CN (2) | CN117242065A (es) |
| AU (2) | AU2022229695A1 (es) |
| BR (1) | BR112023017754A2 (es) |
| CA (2) | CA3210275A1 (es) |
| IL (2) | IL305622A (es) |
| MX (2) | MX2023010316A (es) |
| WO (2) | WO2022183288A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4153564A4 (en) | 2020-05-19 | 2024-06-19 | Cybin IRL Limited | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE |
| WO2024046837A1 (en) * | 2022-08-31 | 2024-03-07 | Cybin Irl Limited | Tryptamine compounds, compositions, and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03008726A (es) * | 2001-03-29 | 2003-12-12 | Lilly Co Eli | N-(2-ariletil)benzilaminas como antagonistas del receptor 5-ht6. |
| TWI318621B (en) * | 2006-08-03 | 2009-12-21 | Nat Bureau Of Controlled Drugs Dept Of Health | A series of deuterium labelled compounds as drug testing standards and their preparations |
| US20090062367A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched eletriptan |
| CA3123737A1 (en) * | 2011-09-09 | 2013-03-14 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| EP3541378A4 (en) * | 2016-11-16 | 2020-10-07 | University of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6A AND THEIR USE IN THE RELIEF OF PROTEINOPATHIA |
| EP4219490A1 (en) * | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220137085A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 3-피롤리딘-인돌 유도체 |
| JP2023513679A (ja) * | 2020-02-04 | 2023-04-03 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| TW202144369A (zh) * | 2020-04-26 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 海鞘素類衍生物及其製備方法與醫藥用途 |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
-
2022
- 2022-03-02 US US18/279,290 patent/US20240166599A1/en active Pending
- 2022-03-02 WO PCT/CA2022/050296 patent/WO2022183288A1/en active Application Filing
- 2022-03-02 US US18/279,293 patent/US20240166630A1/en active Pending
- 2022-03-02 IL IL305622A patent/IL305622A/en unknown
- 2022-03-02 JP JP2023553664A patent/JP2024508922A/ja active Pending
- 2022-03-02 MX MX2023010316A patent/MX2023010316A/es unknown
- 2022-03-02 EP EP22762290.9A patent/EP4301747A1/en active Pending
- 2022-03-02 WO PCT/CA2022/050295 patent/WO2022183287A1/en active Application Filing
- 2022-03-02 CN CN202280032373.XA patent/CN117242065A/zh active Pending
- 2022-03-02 CA CA3210275A patent/CA3210275A1/en active Pending
- 2022-03-02 KR KR1020237033368A patent/KR20230154220A/ko unknown
- 2022-03-02 MX MX2023010317A patent/MX2023010317A/es unknown
- 2022-03-02 BR BR112023017754A patent/BR112023017754A2/pt unknown
- 2022-03-02 KR KR1020237033351A patent/KR20230154219A/ko unknown
- 2022-03-02 AU AU2022229695A patent/AU2022229695A1/en active Pending
- 2022-03-02 CA CA3210270A patent/CA3210270A1/en active Pending
- 2022-03-02 AU AU2022229037A patent/AU2022229037A1/en active Pending
- 2022-03-02 CN CN202280032370.6A patent/CN117500788A/zh active Pending
- 2022-03-02 EP EP22762289.1A patent/EP4301730A1/en active Pending
- 2022-03-02 IL IL305481A patent/IL305481A/en unknown
- 2022-03-02 JP JP2023553660A patent/JP2024508545A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3210270A1 (en) | 2022-09-09 |
| IL305481A (en) | 2023-10-01 |
| WO2022183288A1 (en) | 2022-09-09 |
| IL305622A (en) | 2023-11-01 |
| JP2024508545A (ja) | 2024-02-27 |
| EP4301747A1 (en) | 2024-01-10 |
| CA3210275A1 (en) | 2022-09-09 |
| WO2022183287A1 (en) | 2022-09-09 |
| EP4301730A1 (en) | 2024-01-10 |
| AU2022229695A1 (en) | 2023-09-28 |
| CN117500788A (zh) | 2024-02-02 |
| BR112023017754A2 (pt) | 2023-11-21 |
| MX2023010316A (es) | 2023-11-09 |
| JP2024508922A (ja) | 2024-02-28 |
| US20240166630A1 (en) | 2024-05-23 |
| AU2022229037A1 (en) | 2023-09-28 |
| KR20230154219A (ko) | 2023-11-07 |
| KR20230154220A (ko) | 2023-11-07 |
| US20240166599A1 (en) | 2024-05-23 |
| CN117242065A (zh) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009527A (es) | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. | |
| MX2022009528A (es) | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. | |
| MX2023010317A (es) | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. | |
| JOP20210241A1 (ar) | مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان | |
| MX2007013021A (es) | Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c. | |
| TNSN07007A1 (en) | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha -7- nachr ligands for the treatment of cns diseases | |
| NO20062139L (no) | Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister | |
| EA200900658A1 (ru) | Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами | |
| MXPA05011670A (es) | Derivados de azetidincarboxamida y su uso en el tratamiento de trastornos mediados por el receptor cb1. | |
| PH12012501640A1 (en) | Novel compounds as opioid receptor modulators | |
| MX2009009422A (es) | Derivados de 3-ciano-piridona 1,4-disustituidos y su uso como moduladores del receptor mglur-2 positivo. | |
| MY147588A (en) | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives | |
| MX2007002393A (es) | Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6). | |
| UA115881C2 (uk) | Алкоксипіразоли як активатори розчинної гуанілатциклази | |
| JP2021501151A5 (es) | ||
| TW200624432A (en) | Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto | |
| MX2007005199A (es) | Indolizinas sustituidas y derivados como agentes del sistema nervioso central. | |
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| CR20220160A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| GB0513886D0 (en) | Novel compounds | |
| PT1745010E (pt) | Derivados de ciclo-hexil-1,4-diamina substituídos | |
| CR20220299A (es) | Derivados de becimidazol | |
| UA88910C2 (ru) | Гетероциклические соединения для предотвращения или ослабления симптомов заболеваний, которые лечатся коноплей, и способы их получения | |
| MX2015008733A (es) | Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma. | |
| MX2019004782A (es) | Compuestos, proceso de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de trastornos psiquiatricos y/o trastornos del sueño. |